Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) FCF Margin (2020 - 2024)

Goldenwell Biotech's FCF Margin history spans 5 years, with the latest figure at 16044.94% for Q4 2024.

  • For Q4 2024, FCF Margin rose 2338186.0% year-over-year to 16044.94%; the TTM value through Sep 2025 reached 18438.61%, up 4771229.0%, while the annual FY2024 figure was 88544.6%, 8238159.0% down from the prior year.
  • FCF Margin reached 16044.94% in Q4 2024 per GWLL's latest filing, up from 34353.24% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 16044.94% in Q4 2024 to a low of 36688.92% in Q1 2022.
  • Average FCF Margin over 5 years is 7778.22%, with a median of 2840.0% recorded in 2020.
  • Peak YoY movement for FCF Margin: skyrocketed 3444412bps in 2023, then tumbled -2459019bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 2840.0% in 2020, then soared by 86bps to 394.8% in 2021, then skyrocketed by 109bps to 34.84% in 2022, then plummeted by -21158bps to 7336.92% in 2023, then surged by 319bps to 16044.94% in 2024.
  • Per Business Quant, the three most recent readings for GWLL's FCF Margin are 16044.94% (Q4 2024), 34353.24% (Q2 2024), and 7336.92% (Q4 2023).